Section Arrow
Quote
INAB.NASDAQ
- IN8bio Inc
Quotes are at least 15-min delayed:2025/07/16 09:13 EDT
Pre Market
Last
 2.23
+0.065 (+3.00%)
Bid
2.22
Ask
2.24
High 2.23 
Low 2.16 
Volume 880 
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
2.165 
1-M High
2.5343 
Volume 
-- 
Bid
2.22
Ask
2.24
Day Low
-- 
Open
-- 
1-M Low
2.05 
Market Cap 
7.46M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.22 
20-SMA 2.19 
50-SMA 3.3 
52-W High 26.757 
52-W Low 2.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.20/-5.55
Enterprise Value
10.84M
Balance Sheet
Book Value Per Share
4.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
Pre Market 12.89 +0.01 +0.08%
ZVSAZyVersa Therapeutics----0.000%0PE
Pre Market 0.5317 -0.0173 -3.15%
ZVRAZevra Therapeutics----0.000%-- 
Pre Market 13 +0.21 +1.64%
ZURAZura Bio Limited----0.000%5.54PE
Pre Market 1.3201 +0.0201 +1.55%
ZNTLZentalis Pharmaceuticals----0.000%-- 
Pre Market 1.39 +0.05 +3.73%
Quotes are at least 15-min delayed：2025/07/16 09:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.